LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Andrea J. Bullock, Joseph E. Grossman, Marwan Fakih, Heinz‐Josef Lenz, Michael S. Gordon, Kim Margolin, Breelyn A. Wilky, Daruka Mahadevan, Jonathan C. Trent, Bruno Bockorny, Justin C. Moser, Ani Sarkis Balmanoukian, Benjamin L. Schlechter, Waldo Ortuzar Feliu, Katherine Rosenthal, Bonnie Bullock, Justin Stebbing, James Godwin, Steven O’Day, Apostolia M. Tsimberidou, A. El-Khoueiry
Topics & Concepts
MedicineColorectal cancerCytotoxic T cellImmunotherapyInternal medicineImmune systemT cellProgressive diseaseCancerAntigenAntibodyImmunologyCancer researchOncologyGastroenterologyDiseaseBiologyBiochemistryIn vitroCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmune Cell Function and Interaction